SEC filings and other documents

Strong order growth in China and semi-metrology, with AI and cost savings driving future margins.

AI-driven multi-omics and diagnostics innovation, with strong growth in biopharma and deep tech.

Strong order growth, deep tech expansion, and AI-driven automation fuel future leadership.

Strong Q2 margin and EPS growth, with deep tech and biopharma orders driving robust outlook.

Order momentum, global growth, and cost savings set the stage for margin expansion through 2027.

Directors elected, executive pay approved, and auditors ratified for 2026.

Q1 2026 outperformed expectations; FY2026 guidance reaffirmed with strong margin and EPS growth.

Margin expansion, diagnostics growth, and innovation set the stage for double-digit EPS gains.

2026 guidance targets margin and EPS growth despite ongoing headwinds, with revenue up 4%-5%.

Strong orders and new product launches offset profit challenges; growth focus on biopharma and diagnostics.

Margin expansion and double-digit EPS growth targeted for 2026, driven by cost savings and pricing.

Sequential improvement in Q3, strong bookings, and cost savings set up margin expansion for 2026.

Revenue and EPS fell in Q2; major cost cuts aim to boost margins and EPS in 2026 despite flat growth.

Advanced mass spectrometry launches and strategic shifts drive growth amid market headwinds.